



Enhancing institutional Analysis with Altmetric tools

Ben McLeish
3rd October 2018

Today's Webinar

- Altmetric Development: A Year in Review
- Showcasing Your Institution
 - Demonstrate Global Reach
 - Technical Transfer/Policy Impact
 - Track Academic citations without expensive licenses



Altmetric Development A Year in Review


“The Most Updated Metrics Service”



Data Source Updates

Since January we have added...


- 128 News sources
- 2500 Blogs
- 18 Policy Sources
- 180 Youtube Channels
- We now support 8,500 link shortening services



What Have we Found?

As of 3rd October we have tracked...

- 22.1m Research Outputs
- 87.3m mentions of research
- 10.1 billion API requests globally



New Sources of Attention: Patents!

- 9 Million mentions of research in patent literature
- Date Range from 1975 to Today
- Data Mined, References Extracted

US 9,925,147 B2

Page 5

(56)

References Cited

OTHER PUBLICATIONS

Frutische et al., "Regulation of 25-Hydroxyvitamin D₃-1 α -Hydroxylase and Production of 1 α ,25-Dihydroxyvitamin D₃ by Human Dendritic Cells," *Blood*, 102(9):3314-3316 (2003).

Frohling et al., "Serum 25-hydroxyvitamin D in patients with chronic renal failure on long-term treatment with high doses of vitamin D₂," *Nephron* 26: 116-120 (1980).

Frost et al., "Histomorphometric Changes in Trabecular Bone of Renal Failure Patients Treated with Calcifediol," *Metab. Bone Dis. & Rel. Res.*, 2:285-295 (1981).

Gallagher et al., "Comparison of the Histological Effect and Metabolism of 25-(OH)D and 1,25-(OH)₂D in Rat Bone," p. 399-401, IN: Norman, *Vitamin D: Basic Research and its Clinical Application: Proceedings of the Fourth Workshop on Vitamin D*, Berlin, West Germany, Feb. 1979.

Ghazali et al., "Is low plasma 25-(OH) vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?" *Kidney International* 55:2169-2177 (1999).

Gibson, ed., *Product optimisation. Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form*, 295-8 (2004).

Granja et al., "Studies on the Opening of Dioxanone and Acetal

Hollis, "Circulating 25-Hydroxyvitamin D Levels Indicative of Vitamin D Sufficiency: Implications for Establishing a New Effective Dietary Intake Recommendation for Vitamin D," *J. Nutr.* 135: 317-322 (2005).

Horst et al., "A Sensitive Competitive Protein Binding Assay for Vitamin D in Plasma," *Steroids*, 37:581-592 (1981).

Horst et al., "Discrimination in the Metabolism of Orally Dosed Ergocalciferol and Cholecalciferol by the Pig, Rat and Chick," *Biochem. J.*, 204:185-189 (1982).

Horst et al., "Rat cytochrome P450C24 (CYP24) does not metabolize 1,25-dihydroxyvitamin D₂ to calcitric acid," *J. Cell Biochem.*, 88:282-285 (2003).

Hottelart et al., "Ostéodystrophie rénale (2): son traitement chez l'insuffisant rénal avant la dialyse" *Nephrologie* 21(6):275-282 (2000) [reference in French].

Houghton et al., "The Case Against Ergocalciferol (Vitamin D₂) as a Vitamin Supplement," *Am. J. Clin. Nutr.*, 84:694-697 (2006).

Hunt, et al., "A Comparison of the Toxicity of Ergocalciferol and Cholecalciferol in Rhesus Monkeys (Macaca mulatta)," *J. Nutrition*, 102:975-986 (1972).

Hussar, "New Drugs of 1999," *J. Am. Pharmacist. Assoc.* 40(2):181-229 (2000).

International Search Report for Application No. PCT/US2007/061521, dated Jul. 17, 2007.

International Search Report of PCT/US2008/061579 dated Aug. 21,

2018-03-27
12:00 AM UTC

9

Method for treating secondary hyperparathyroidism in CKD

Patent citation

A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be...



Vitamin D₂ is Much Less Effective than Vitamin D₃ in Humans

Article in The Journal of Clinical Endocrinology & Metabolism, November 2004



Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety

Article in American Journal of Clinical Nutrition, January 1999



Hypovitaminosis D in Medical Inpatients

Article in New England Journal of Medicine, March 1998



C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status.

Article in The Journal of Clinical Endocrinology & Metabolism, May 2006



Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries

Article in International Journal of Cancer, January 2003





COMPARISON OF ORAL 25-HYDROXYCHOLECALCIFEROL, VITAMIN D, AND ULTRAVIOLET LIGHT AS DETERMINANTS OF CIRCULATING 25-HYDROXYVITAMIN D

Article in The Lancet, September 2003

New Sources of Attention: Patents!

- New Tab for all of an item's patent mentions
- Global View of patents also found in the timeline



Policy Documents

(A few notable examples)



**CHATHAM
HOUSE**

The Royal Institute of
International Affairs





Council of Canadian Academies
Conseil des académies canadiennes

PEMBINA
i n s t i t u t e





New Source: Academic Citations



New Source: Academic Citations



Citations by year



Service Updates:

Explorer API v2.0

- Includes Department and Researcher-level data feeds for attention to research
- Create an API feed for any group of items (up to 25,000 at once.)
- Intuitive and easy to create queries specific to your institutional structure




Service Updates:

The Highlights Page:

A Bird's Eye View of Your Attention - and all attention


- Demographic data for the full institution's mentions
- Latest Highlights
- Top Engaging sources / social media accounts
- Score distribution histogram
- Attention broken down by Journal Title



Service Updates:

The Highlights Page:

- *Documentation fully rewritten and updated*



The screenshot shows a web browser window with the URL <https://www.altmetric.com/explorer/documentation/api>. The page features the Altmetric Explorer logo and a navigation sidebar on the left. The sidebar contains three main sections: TOPICS, ENDPOINTS, and APPENDIX. The TOPICS section includes links for Introduction, JSON API, Pagination, API Keys, Reset API Keys, and Authentication. The ENDPOINTS section includes links for Research Outputs, Attention Summary, Demographics, Mentions, and Journals. The APPENDIX section includes a link for Mention Types. The main content area is titled "EXPLORE THE ALTMETRIC DATABASE" and contains two sections: "Altmetric Explorer API" and "JSON API". The "Altmetric Explorer API" section describes the API's purpose and provides a paragraph of text. The "JSON API" section describes the API's format and provides a paragraph of text.

Altmetric EXPLORER

EXPLORE THE ALTMETRIC DATABASE

Altmetric Explorer API


The Altmetric Explorer API gives programmatic access to all of the research outputs and attention data within your instance of the Altmetric Explorer. For customers with an institutional data implementation, imported information such as author names, department or group names, and institutional research outputs are all searchable via the Explorer API. This data is very similar to the data contained in the CSV spreadsheet exports. However, with the API you are able to access it programmatically and check for updates.

You will need some programming experience in order to pull data from this API.

JSON API

The API is generally following the [JSON API specification](#). That means you'll find many objects in a standardized format.

Customers are integrating attention data more broadly in repositories



The screenshot shows the London Institute website with a search bar containing 'debunk'. The results are displayed in a grid. The first result is 'Debunking in a world of tribes' by F. Zollo, A. Bessi, M. Vicario, G. Caldarelli, L. Shekht... from PLOS ONE, with 312 views. Below this, there are several other results from various sources, including The Washington Post, POST, Science ORF, Növa, Winnipeg Free Press, and Pieuvre. Each result includes a small image or logo and a brief description of the article. The website has a dark header with navigation links: London Institute, Papers, People, Funding, Press, LIMS Ventures, Support us, and a Log in button. A search bar is located below the header, and a sidebar on the right shows 'Citation updates' and 'Online media updates'.

- Attention Feed for all items
- New coverage is auto-populated below a piece of research
- More and more repositories adding badges around the world




Quick Search bar with Advanced Autocomplete

Responsive

Relevant

Customised per Institution




The screenshot displays a search bar with the text 'ra' entered. Below the search bar, there are several sections of autocomplete results:

- Keywords:** A blue button labeled 'Output contains keywords **ra**'.
- Title:** A text input field with the placeholder 'Output title contains **ra**'.
- Verified departments from Lilliput University (API):** A list of departments including 'Circulatory and Respiratory Health' and 'Strategic Initiatives'.
- Publishers:** A list of publishers including 'Dawsonera', 'British Institute of Radiology', 'Coimbra University Press', 'Taylor & Francis', and 'American Society of Agricultural and Biological Engineers'. Below the list is a link 'Choose from 12 other matching publishers...'.
- Verified authors from Lilliput University (API):** A list of authors including 'Rachel Wilder' (GR11051), 'Ramona Hamm' (GR11032), 'Lora Ellis' (Healthy and Productive Work, GR11046, GR11045), 'Vera Shropshire' (GR11032), and 'Robyn Moran' (GR11043, GR11039, GR11041). Below the list is a link 'Choose from 4 other matching authors...'.









Rebuilt: Query an ORCID for altmetrics




Empowering Institutions



What attention does our institutions' highest cited work get?

Sort by: Dimensions citations	
 <p>170</p>	<p>Global cancer statistics Article in CA: A Cancer Journal for Clinicians, February 2011 ■ 22,276 Dimensions citations</p>
 <p>143</p>	<p>Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA... Article in PLoS Medicine, July 2009 ■ 11,518 Dimensions citations</p>
 <p>478</p>	<p>Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the... Article in Archives of General Psychiatry, June 2005 ■ 8,349 Dimensions citations</p>
 <p>266</p>	<p>Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Article in New England Journal of Medicine, August 2010 ■ 6,909 Dimensions citations</p>
 <p>58</p>	<p>Statistical significance for genomewide studies Article in Proceedings of the National Academy of Sciences of the United States of America, July 2003 ■ 5,566 Dimensions citations</p>
 <p>48</p>	<p>Harmonizing the Metabolic Syndrome Article in Circulation, October 2009 ■ 5,339 Dimensions citations</p>

What innovations are we spurring?





Report, Download, Get Mentions via API

Mention Type	Mention Date	Mention Title	Country	Mention URL	Research Output Title	Journal/Collc Output Type	Publication	Altmetric	Att	Details	Page	DOI	IS
Patent	27/03/2018 00:00	Method and apparatus accounting for independent		https://app.dimensions.ai/details/patent/US-9927940-B2	The magical number 4 in short-term memory: A rec Behavioral & Article		01/02/2001	78		https://www.10.1017/s0140			
Patent	20/03/2018 00:00	Methods for detecting and monitoring endocrine di		https://app.dimensions.ai/details/patent/US-9921211-B2	Hormones and Endocrine-Disrupting Chemicals: Low Endocrine Re Article		14/03/2012	402		https://www.10.1210/er.20			
Patent	13/03/2018 00:00	Drug formulations		https://app.dimensions.ai/details/patent/US-9913856-B2	Improved Survival with Ipilimumab in Patients with New England Article		19/08/2010	266		https://www.10.1056/nejm			
Patent	13/03/2018 00:00	1-aryl-3-aminoalkoxy pyrazoles as sigma ligands en		https://app.dimensions.ai/details/patent/US-9914705-B2	Global Prevalence of Diabetes Estimates for the yei Diabetes Car Article		26/04/2004	43		https://www.10.2337/dia			
Patent	06/03/2018 00:00	Receptor subtype and function selective retinoid an		https://app.dimensions.ai/details/patent/US-9907768-B2	Improved Survival with Ipilimumab in Patients with New England Article		19/08/2010	266		https://www.10.1056/nejm			
Patent	06/03/2018 00:00	Methods for treating bipolar disorder		https://app.dimensions.ai/details/patent/US-9907777-B2	Lifetime Prevalence and Age-of-Onset Distributions Archives of C Article		01/06/2005	479		https://www.10.1001/archp			
Patent	30/01/2018 00:00	Methods of treating metabolic disorders		https://app.dimensions.ai/details/patent/US-9878010-B2	Prevalence of hepatic steatosis in an urban populati Hepatology Article		01/01/2004	24		https://www.10.1002/hep.2			
Patent	30/01/2018 00:00	Infectious plasmodium sporozoites grown in vitro		https://app.dimensions.ai/details/patent/US-9878026-B2	The economic and social burden of malaria Nature Article		07/02/2002	42		https://www.10.1038/41568			
Patent	16/01/2018 00:00	Insulin derivatives for diabetes treatment		https://app.dimensions.ai/details/patent/US-9867869-B2	Global Prevalence of Diabetes Estimates for the yei Diabetes Car Article		26/04/2004	43		https://www.10.2337/dia			
Patent	09/01/2018 00:00	Predictive biomarkers for CTLA-4 blockade therapy		https://app.dimensions.ai/details/patent/US-9863935-B2	Improved Survival with Ipilimumab in Patients with New England Article		19/08/2010	266		https://www.10.1056/nejm			
Patent	09/01/2018 00:00	LPT-723 and immune checkpoint inhibitor combinat		https://app.dimensions.ai/details/patent/US-9861621-B2	Improved Survival with Ipilimumab in Patients with New England Article		19/08/2010	266		https://www.10.1056/nejm			
Patent	02/01/2018 00:00	Tripeptide epoxyketone compound constructed by h		https://app.dimensions.ai/details/patent/US-9856288-B2	Global cancer statistics CA: A Cancer Article		04/02/2011	170		https://www.10.3322/caac.2			
Patent	02/01/2018 00:00	Treatment of cancer by manipulation of commensa		https://app.dimensions.ai/details/patent/US-9855302-B2	Improved Survival with Ipilimumab in Patients with New England Article		19/08/2010	266		https://www.10.1056/nejm			
Patent	26/12/2017 00:00	Sublingual administration of statins		https://app.dimensions.ai/details/patent/US-9849083-B2	Statins for the primary prevention of cardiovascular Cochrane da Article		31/01/2013	323		https://www.10.1002/14651			
Patent	19/12/2017 00:00	Sigma ligands for use in the prevention and/or trea		https://app.dimensions.ai/details/patent/US-9844516-B2	Global Prevalence of Diabetes Estimates for the yei Diabetes Car Article		26/04/2004	43		https://www.10.2337/dia			
Patent	19/12/2017 00:00	Bacterial RNAs as vaccine adjuvants		https://app.dimensions.ai/details/patent/US-9844592-B2	Statistical significance for genomewide studies Proceedings Article		25/07/2003	58		https://www.10.1073/pnas.			
Patent	12/12/2017 00:00	Combination of rose bengal and systemic immunon		https://app.dimensions.ai/details/patent/US-9839688-B2	Improved Survival with Ipilimumab in Patients with New England Article		19/08/2010	266		https://www.10.1056/nejm			
Patent	12/12/2017 00:00	Compositions and methods for altering second mes		https://app.dimensions.ai/details/patent/US-9840533-B2	Improved Survival with Ipilimumab in Patients with New England Article		19/08/2010	266		https://www.10.1056/nejm			
Patent	28/11/2017 00:00	Brazzen multiple variants of increased sweetness, i		https://app.dimensions.ai/details/patent/US-9826773-B2	Aspartame: a safety evaluation based on current us Critical Revie Article		10/10/2008	337		https://www.10.1080/10408			
Patent	21/11/2017 00:00	Pharmaceutical combination for improving glycemi		https://app.dimensions.ai/details/patent/US-9821032-B2	Global Prevalence of Diabetes Estimates for the yei Diabetes Car Article		26/04/2004	43		https://www.10.2337/dia			
Patent	21/11/2017 00:00	T-cell receptor-deficient T cell compositions		https://app.dimensions.ai/details/patent/US-9822340-B1	Correction to Pfister, Schroeder, and Kunde (2013) Proceedings Article		01/01/2013	501		https://www.10.1073/pnas			
Patent	07/11/2017 00:00	Combination of local and systemic immunomodulat		https://app.dimensions.ai/details/patent/US-9808524-B2	Improved Survival with Ipilimumab in Patients with New England Article		19/08/2010	266		https://www.10.1056/nejm			
Patent	02/11/2017 00:00	NOVEL CRISPR ENZYMES AND SYSTEMS		https://app.dimensions.ai/details/patent/WO-2017189308	Correction to Pfister, Schroeder, and Kunde (2013) Proceedings Article		01/01/2013	501		https://www.10.1073/pnas			
Patent	01/11/2017 00:00	USE OF MICROVESICLES IN DIAGNOSIS AND PROG		https://app.dimensions.ai/details/patent/EP-3239305-A2	Anemia of chronic disease. New England Article		11/03/2005	40		https://www.10.1056/nejm			
Patent	31/10/2017 00:00	Anti-hepcidin antibodies and uses thereof		https://app.dimensions.ai/details/patent/US-9803011-B2	Anemia of chronic disease. New England Article		11/03/2005	40		https://www.10.1056/nejm			
Patent	17/10/2017 00:00	Use of sigma ligands in diabetes type-2 associated		https://app.dimensions.ai/details/patent/US-9789117-B2	Global Prevalence of Diabetes Estimates for the yei Diabetes Car Article		26/04/2004	43		https://www.10.2337/dia			
Patent	17/10/2017 00:00	Use of sigma ligands in opioid-induced hyperalgesia		https://app.dimensions.ai/details/patent/US-9789115-B2	Global Prevalence of Diabetes Estimates for the yei Diabetes Car Article		26/04/2004	43		https://www.10.2337/dia			
Patent	17/10/2017 00:00	Combination of anti-KIR and anti-CTLA-4 antibodies		https://app.dimensions.ai/details/patent/US-9789182-B2	Improved Survival with Ipilimumab in Patients with New England Article		19/08/2010	266		https://www.10.1056/nejm			
Patent	12/10/2017 00:00	USE OF HETERODIMERIC IL-15 IN ADOPTIVE CELL TI		https://app.dimensions.ai/details/patent/WO-2017177063	Improved Survival with Ipilimumab in Patients with New England Article		19/08/2010	266		https://www.10.1056/nejm			
Patent	10/10/2017 00:00	Sigma ligands for the prevention and/or treatment		https://app.dimensions.ai/details/patent/US-9782483-B2	Global Prevalence of Diabetes Estimates for the yei Diabetes Car Article		26/04/2004	43		https://www.10.2337/dia			
Patent	10/10/2017 00:00	Treatment and prevention of Gardnerella vaginalis		https://app.dimensions.ai/details/patent/US-9783580-B2	The spread of obesity in a large social network over New England Article		24/07/2007	1427		https://www.10.1056/nejms			
Patent	26/09/2017 00:00	Compositions and methods for cancer immunother		https://app.dimensions.ai/details/patent/US-9770467-B2	Improved Survival with Ipilimumab in Patients with New England Article		19/08/2010	266		https://www.10.1056/nejm			
Patent	26/09/2017 00:00	Compounds, pharmaceutical composition and meth		https://app.dimensions.ai/details/patent/US-9770435-B2	Global Prevalence of Diabetes Estimates for the yei Diabetes Car Article		26/04/2004	43		https://www.10.2337/dia			
Patent	12/09/2017 00:00	Nanoparticle complexes of anti-CD20 antibodies, al		https://app.dimensions.ai/details/patent/US-9757453-B2	Improved Survival with Ipilimumab in Patients with New England Article		19/08/2010	266		https://www.10.1056/nejm			
Patent	12/09/2017 00:00	Devices and methods to monitor HIV-infection in pr		https://app.dimensions.ai/details/patent/US-9759709-B1	Effectiveness and safety of tenofovir gel, an antiret Science Article		18/07/2010	209		https://www.10.1126/scien			
Patent	12/09/2017 00:00	Sigma ligands for potentiating the analgesic effect		https://app.dimensions.ai/details/patent/US-9757358-B2	Global Prevalence of Diabetes Estimates for the yei Diabetes Car Article		26/04/2004	43		https://www.10.2337/dia			
Patent	12/09/2017 00:00	Compositions and methods for treating neuropathic		https://app.dimensions.ai/details/patent/US-9758786-B2	Improved Survival with Ipilimumab in Patients with New England Article		19/08/2010	266		https://www.10.1056/nejm			



Demonstrating “Additionality” (REF)



Altmetric is a Data Resource For your institution's researchers

[Who are we for?](#) [Products](#) [About altmetrics](#) [About our data](#)

Researcher Data Access Program

Providing free access to Altmetric data for those wanting to study how research is shared and communicated online

Supporting the scientometrics community

Altmetric is committed to helping others drive forward the field of altmetrics research through investigating our data. That's why we offer our data free of charge to those who wish to understand patterns in scholarly communication across the Web.

Data access is granted only for one-time, limited duration research projects. If you are interested in using our data for evaluative purposes, including for building dashboards, please check out our [products listing](#).

Researchers who wish to enroll in the Researcher Data Access Program must agree to a number of terms (described fully in the Program application form), including making one's work Open Access, abiding by our official branding guidelines and attribution requirements, and sharing resulting presentations and publications with Altmetric.

Before requesting access, please learn more below about what information our data does and does not include.

We offer free access in several formats suited to all levels of technical expertise.

Raw database (JSON)	<ul style="list-style-type: none">• For researchers working on a specific academic, one-off project• Must give attribution to Altmetric when using data, let Altmetric know what project you're working on with the data and provide updates• Must have extensive prior experience working with JSON	<ul style="list-style-type: none">• Run queries and retrieve <i>full text of mentions</i> (excluding Tweets due to licensing restrictions).• Allows for faster, local data processing (as compared to API data retrieval).• Best suited for individuals with extensive programming experience.
Custom data retrieval (\$)	<ul style="list-style-type: none">• Because of the development resources involved in retrieving custom data, we charge for this service (at-cost)• For researchers working on a specific academic, one-off project• Must give attribution to Altmetric when using data, let Altmetric know what project you're working on with the data and provide updates	<ul style="list-style-type: none">• For Explorer data: CSV exports of <i>counts and full-text mention</i> data for queries based on keywords in output titles and abstracts, journal titles, PubMed terms, publisher names, publication dates, and mention timeframes. Suited for those without programming experience.• For JSON data: Run programmatic queries and retrieve <i>full text of mentions</i> (excluding Tweets due to licensing restrictions). Allows for faster, local data processing (as compared to API data retrieval). Best suited for individuals with programming experience.



More to come...

- Searching by Field of Research
- Searching by Affiliation
- Biweekly updates to data and features to continue
- We are continuing to consult regularly with customers
- Now adding policy documents on a monthly basis (300,000 new mentions data mined in 2018 alone)

We have developed more in 9 months than others have in four years. And we are going to keep it up!





Thank you!

ben@altmetric.com

+44 750 6543 635

@benmcleish

@altmetric